THERAPY DOSSIER · th-12862333721b

LianQinJieDu (LQJD) decoction, 60% ethanol dry extract; main ingredients berberine, astragalus and scutellaria

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28972887 ↗2017Reported benefit

Lianqinjiedu decoction attenuates LPS-induced inflammation and acute lung injury in rats via TLR4/NF-kB pathway.

RatEndotoxin/LPSSprague-Dawleyn = 48 rats randomised into six groups (per-group n not stated)Oral administration0.61, 1.22 and 2.44 g/kg (low, medium and high dose); posit…1 h before intraperitoneal LPS injection (pre-treatment)

Model: Lipopolysaccharide-induced acute lung injury; LPS 0.005 g/kg (E. coli 055:B5) by intraperitoneal injection

LQJD reduced the LPS-induced rise in body temperature, lowered serum TNF-alpha and IL-6, and reduced inflammatory infiltration and alveolar disruption on histology. TLR4 and NF-kBp65 were down-regulated at both mRNA and protein level in lung tissue.

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…